Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Antimalarial chemoprophylaxis and the risk of neuropsychiatric disorders
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 2355884
Author(s) Schneider, Cornelia; Adamcova, Miriam; Jick, Susan S; Schlagenhauf, Patricia; Miller, Mary K; Rhein, Hans-Georg; Meier, Christoph R
Author(s) at UniBasel Schneider, Cornelia
Meier, Christoph R.
Year 2013
Title Antimalarial chemoprophylaxis and the risk of neuropsychiatric disorders
Journal Travel medicine and infectious disease
Volume 11
Number 2
Pages / Article-Number 71-80
Abstract Case reports and epidemiological studies have associated the use of mefloquine with neuropsychiatric adverse events.; We used the General Practice Research Database to conduct a follow-up study with a nested case-control analysis. We assessed the risk of developing first-time anxiety, stress-related disorders/psychosis, depression, epilepsy or peripheral neuropathies in patients using mefloquine, chloroquine and/or proguanil, or atovaquone/proguanil for malaria chemoprophylaxis, as compared to unexposed travelers.; Compared to non-users of antimalarials, the adjusted odds ratio in the nested case-control analysis for users of mefloquine, chloroquine and/or proguanil, or atovaquone/proguanil were 0.71 (95% CI 0.56-0.90), 1.04 (95% CI 0.74-1.46), and 0.73 (95% CI 0.61-0.86) for anxiety or stress-related disorders combined, 0.54 (95% CI 0.41-0.71), 1.06 (95% CI 0.71-1.59), and 0.75 (95% CI 0.62-0.91) for depression, 0.69 (95% CI 0.35-1.36), 1.41 (95% CI 0.54-3.67), and 0.75 (95% CI 0.42-1.36) for epilepsy, and 1.22 (95% CI 0.50-2.99), 1.59 (95% CI 0.41-6.15), and 1.05 (95% CI 0.54-2.03) for neuropathies, respectively. The risk of all outcomes was higher in females than in males across all exposure categories.; The risk of neuropsychiatric disorders was similar for users and for non-users of anti-malarial chemoprophylaxis, with evidence for elevated risks in some subgroups.
Publisher Elsevier
ISSN/ISBN 1477-8939
edoc-URL http://edoc.unibas.ch/41115/
Full Text on edoc No
Digital Object Identifier DOI 10.1016/j.tmaid.2013.02.008
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/23541791
ISI-Number WOS:000320413200001
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.334 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
28/03/2024